Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganluotong is a Traditional Chinese Medicine (TCM) therapeutic candidate developed by Sichuan Yatai Pharmaceutical Co., Ltd. It is primarily indicated for the treatment of portal hypertension in patients with chronic hepatitis B-related liver cirrhosis. Formulated as a chewing tablet, Ganluotong is intended to reduce portal vein pressure and improve liver function by addressing hepatic fibrosis and microcirculatory disturbances. Clinical development has reached Phase 2 in China, with trials such as CTR20140184 focusing on evaluating its safety, efficacy, and optimal dosing regimen in the target patient population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ganluotong.